less equipotent, although this is not proven by randomized trials. In limited disease (LD) an overall response COR) rate of 80-95% and a complete response (CR) rate of at least 50-60% with a median survival betw een 12 and 16 months can be achieved, Corresponding num bers in extensive disease (ED) are an OR rate of 60-80% and a CR rate of 15-30% w ith a median survival betw een 7 and 12 months.
Introduction cancer (SCLC) is poor at 5 -12 weeks. In 1969 it was reported that cyclophosphamide prolonged the sur vival of patients with advanced SCLC,1 In the 1970s several combination chemotherapy regimens were rates and longer survival than single drug therapy. Nowadays, eye tine (CAV), cyelophosphamide/adriamycin/etoposide (CDE), cisplatin/etoposide (PE) and (vincristine/) ifiosiamide/carboplatin/etoposide (VICE or ICE) are the most frequently used combinations. At standard dose these combinations are considered to be more or • -m Correspondence to VCG Tjan-Heijnen nations should be used in an attempt to circumvcnt the developm ent of drug resistance. 12 Several large randomized trials evaluated the impact of alternating regimens, but could not show any major survival )j | | advantage, ' ' ' However, in these trials only partial non-cross-resistant drugs were used and this may be | î nsufficient to test the hypothesis.
There is still an on-going debate on the impor tance of dose in SCLC treatment. Skipper and (i/) 1 )9 7 R apid Scie rice Pi t hi is hers A ni i-Ca h cer I ) i v igs • Vo! 8 * 19( J 1 5 4 9 Schabel showed a clear dose-response relationship of 30-40% in SCLC patients, while complete re fer cyclophosphamide and other anticancer drugs in sponses are seldom seen. 19 Souhami and colleagues animal tumor models, suggevsting that dose is critical showed that in untreated LD patients 1 6 0to tumor cell kill. 16 The concept of dose intensiftca-200 m g/kg cyclophosphamide, administered during tion has been tested in patients with SCLC. Dose one course, produced an OR rate of 84% and a CR rate of 56%, indicating that there is a clear dose- 20 response relationship. These promising results between courses. Higher doses per course can be could not be improved by giving a second cycle of high-close cyclophosphamide, implying that there was a quick emergence of drug resistance. 21 Etoposide in a conventional dose has shown response rates of 40-60% in previously untreated SCLC patients,22 W hen given at a higher dose conflicting data have been reported.23" 2* ' Other agents that do have antitumor activity in SCLC have not been studied for VCG Tjan-Heijnen et al.
intensification can be achieved by delivering a high er dose per course and/or by shortening intervals delivered in the first course(s), i.e. early intensifica tion, or last course(s), i.e. late intensification, or during all courses. In the first part of this paper, we will discuss dose intensification studies performed in the pre-growth factor period, with attention fo cussed on randomized trials. In the second part we will review the role of granulocyte colony stimulat ing factor (G-CSF) and granulocyte macrophage a _ dose-response correlation, w hen given as a single colony stimulating lactor (GM-CSF) as adjuncts to agent at a megadosage. For etoposide a schedule dependency has been shown, with increasing activity w hen given over several consecutive days,26 which 27 may also be the case for cyclophosphamide.
standard-close and intensified chemotherapy. Before discussing the individual studies, some general remarks concerning definitions have to be made. The amount of anticancer drugs given during a certain time period (m g/m 2 per week or day) is referred to as dose intensity (DI) .17 Projected (planned) DI is obviously not the same as actually delivered DI, but the latter, more important, informa-In a meta-analysis it w as concluded that the DI of Early intensification studies tion is seldom reported. Another frequently vised term is relative DI (RDI), i.e. the ratio of the DI of the first two courses was not consistantly correlated w ith response and survival in SCLC. 28 However, in the investigated regimen and the DI of another usual this analysis studies in both chemonaive and re standard regimen. The average DI for combination lapsed patients w ere taken together. Dose intensifichemotherapy is calculated by the sum of Dis of cation studies w ere excluded, because the first two each individual agent divided by the num ber of courses would not be representative lor the whole agents in that combination, with the assumption that treatment period. W hen having a closer look at the the different drugs are equivalently active, It is tables, it shows that the majority of trials had a RDI important to note that the reported DI is often of smaller than 1 (com pared to a reference regimen), calculated only for those cycles that are indeed indicating that in the majority of trials standard delivered. This may be misleading, when for exam-versus low dose was compared. Moreover, the range pie a substantial number of patients have discontin-of RDIs was small and it may have been difficult to ued treatment prematurely, because in these patients assess any correlation at all. The validity of this kind the DI may be high, although the delivered total of retrospective analysis has also been questioned by dose is actually low, The delivered total dose is others. 29 The results of this analysis may therefore therefore valuable additional information, but this is not be used as an argum ent against dose intensificaoften not separately reported, tion studies, In phase II studies of up-front early intensification, megadoses of cyclophospham ide (up to 7.0 g /n r ) and/or etoposide (up to 1,5 g /n r2) were prescribed, with or w ithout autologous bone marrow support/ 0^4 These regim ens were very toxic and, despite promising high CR rates, survival seemed not to be improved. Direct comparisons of chemotherapeutic agents at different dosages have seldom been reported in Cyclophosphamide is a commonly used agent in SCLC. An old randomized study showed a benefit of between low and standard dose was made and the pivotal question is not w h eth er standard dose is better than Low dose, but w h eth er high dose is better than standard dose. To address this question, four randomized studies have assessed the im pact of early intensification o f com m only used agents (see Table l ) / 6-'*9 These trials differ in selection of patients, choice of regim en and degree of intensifi cation. Patients w ere random ized to receive a num ber of initial courses (1 -4 ) at either intensified or standard dose. In the subsequent cycles all patients received courses at standard close. The increase in delivered total dose w as relatively larger than the encouraging, but may be due to chance, as the difference in dose intensity between both arms is remarkably small. On the other hand, it may be a fact that dose escalation is especially worthwhile in LD patients (low volume disease) and this may also explain the lack of any benefit in the other early intensification studies. Another explanation lor these disappointing results may be the num ber of patients, that may have been too small to draw definite conclusions in three of four trials. Further more, the doses of a num ber of drugs were increased, although the phase II data of these drugs are often incomplete when looking ibr a d o se-
Dose intensification without growth factors
Intensified treatm ent o f sm all cell lung cancer increase in dose intensity. As can be expected, response relationship in SCLC Moreover, the degree toxicity was in general m ore severe in the intensi-of intensification may be still too low and megalied cycles, although this w as manageable. A sig-doses as used in some phase II studies may still bê
The French trial nificantly better CR rate by early intensification was achieved in only one study, but this was not translated into a better survival, was the only trial that show ed an im proved survival (2- year survival 43 versus 26% in favor of the intensified arm; p = 0 .02), w ith a nearly significant difference in median duration of CR (540 versus 358 days; p -0 .06).38 This trial was based on a retrospective analysis in 131 consecutive treated LD patients, which show ed that a 20% increase in initial closes of cyclophospham ide and cisplatin, *10 produced an increase of 2-year survival of 2 0 % ! The survival benefit seen in the French trial is worthwhile to evaluate in a randomized setting.
Late intensification studies
Norton and Simon proposed a mathematical model, in w hich they argued that small tumors may be less sensitive to chemotherapy due to a reduced growth fraction. 0 Therefore, they suggested to administer intensified chem otherapy of a relative brief duration, in case a CR by the induction therapy had been obtained. To test their theory a number of small phase II trials w ere conducted.12 S1 In most of these dOnly compared for those courses in which HD chemotherapy was prescribed.
* p < 0.003, ** p < 0.05, p = 0*02, p < 0.0001. trials only one high-close cycle was given with eye I op ho sphamide (4.0-7 .0 g/ m 2) and/o r e to p o 8 id e (1 -3.5 g /m 2). In 20-50% of patients with a partial II trials, four to seven drugs w ere administered weekly in an alternating fashion over a total of 9 -1 6 weeks. * In these regimens, most drugs were response (PR) after induction therapy, a CR after late delivered at an increased DI p er course, but in intensification was achieved, although in general of comparison w ith conventional schedules sometimes short duration. In this highly selected patient popu-at the cost of total dose. The regimens appeared to lation long-term disease-free survival varied from 5 he feasible in the majority of patients and promising to 20% and therefore seems not superior to conven tional regimens.
In the one randomized late intensification study that has been reported by Humblet e t a l., it was assessed w hether after live induction cycles (of six different drugs) a last intensified cycle would pro duce better results than an additional standurd-dose 52 Patients were eligible for randomization in case after induction a CR or PR was obtained in LD and a CR in ED. This was the case in only 40 of 101 registered patients; an additional five ED patients with PR were abusively also randomized. The last Toxicity w as tolerable in both arms. Grade III and IV neutropenia occurred more frequently in the stan-high response rates were reported. Only two phase III trials testing this concept have been reported. 56, 57 In the first, 223 patients were randomized to receive either the weekly regimen (cyclophosphamide 500 m g /m 2, doxorubicin 25 m g /m 2 and etoposide 120 m g /m 2 in w eek 1, cisplatin 60 m g/m 2 and vindesine 3 m g /m 2 in week 2 , vincristine 2 mg and m ethotrexate 100 m g /m 2 in week 3; 6 times re peated) or six three-weekly courses of CDE (1000, 50, 3 X 80 m g /m 2, respectively).56 Response rates and survival show ed no significant standard-dose cycle consisted of cyclophosphamide 750 m g/m 2, etoposide 120 m g/m 2 X 5 orally and BCNIJ 60 m g/m 2. In the intensified cycle the doses of these three agents were increased by 700, 67 and 4900%, respectively, with autologous bone marrow rescue. After the intensified cycle, the CR rate increased from 39 to 79%, while in the standard arm the response rate did not increase after the last conventional dosed cycle. Although median relapsefree survival after randomization was significantly better in the intensified arm (28 versus 10 weeks, p -0.002), there was no more than a trend toward improvement in median overall survival (68 versus dard arm (59 versus 76% of patients, p = 0.03). In another random ized trial, 438 patients received either w eekly chemotherapy (12 alternating cycles of ifosfamide 2 g /m 2/doxorubicin 25 m g/m 2 and cisplatin 50 m g /m 2/etoposide 2 X 75 m g/m 2) or six three-weekly alternating cycles of standard dose CAV/PE (600, 50, 2 and 60, 3 X 120 m g/m 2, re spectively).57 Again, no differences in response nor in survival could be demonstrated. The weekly schedule w as less feasible and more often treatment had to be reduced or delayed, with the consequence that only 74% of planned DI could be delivered, 55 weeks, ^ = 0.13), This disappointing result may while 93% of planned DI of the standard regimen be explained by the small size of the study, the could be given, In these randomized studies different inclusion of ED patients and by the fact that during late intensification drugs were used that were also part of the induction regimen. Patients with a partial remission are unlikely to be cured by a last dose escalation; however, in this study among four long term survivors two were partial responders to the agents w ere used in the different arms. Therefore, no exact com parisons concerning delivered dose and DI can be made. The results of a collaborative trial conducted by the Eastern Cooperative Oncol ogy Group the Southwest Oncology Group, and the National Cancer Institute of Canada have to be induction regimen. Despite the support of autolo-awaited. In their study the weekly regimen consistgous bone marrow infusion 17% toxic deaths were ing of cisplatin, vincristin, doxorubicin and etoposeen during aplasia in the intensified arm, compared side (CODE)55 is com pared with standard dose CAV/ to no toxic deaths in the standard treatment arm, PE. and this may also have contributed to the final bad outcome. Lastly, no thoracic irradiation was given and this appeared to be the primary site of relapse
Role of growth factors in
in the majority of patients.
Acceleration studies chemotherapy for SCLC

Growth factors and chemotherapyinduced myelosuppression
A third way to increase the DI is delivering chemo therapy at shortened intervals. In three phase Colony stimulating factors are physiologically occurring glycoproteins that control proliferation I n te n s ifie d t r e a t m e n t o f s m a l l c e ll lu n g c a n c e r and differentiation of m ultipotent and lineage-Growth factors as adjunct to standard- This increase is dose dependent, although there is a considerable overlap. Alter discontinuation a rapid fall in circulating neutrophils to pre-treat ment levels is seen w ithin 2 -4 days. G-CSF primarily affects the peripheral counts of neutro phils. GM-CSF produces a similar dose-dependent increase in neutrophils and produces also a signifi cant increase in m onocytes and eosinophils.66' "08
Both grow th factors produce an increased bone marrow cellularity w ith increased m yeloid-erythroid ratio.60,67,68 G-CSF is associated w ith only minimal toxicity, even at 60 /¿g/kg/day, essentially , never been reported.
The augm entation of circulating neutrophils by G-CSF and GM-CSF suggested a role in improving recovery of myelopoiesis after chemotherapy. In a phase II study in SCLC patients, G-CSF was given to each patient for 14 days on alternate (odd or even) cycles of three-weekly chem otherapy. G-CSF doses varied from 1 to 40 /vg/kg/day and was com menced 24 h after the last chem otherapy
The combination of fever and neutropenia is a lifethreatening complication of chem otherapy Despite immediate administration of broad-spectrum i.v. anti biotics, mortality remains approximately ' 10% among patients w ith docum ented infections and 2% lbr all cases of fever. 76 The most important prognostic factor for the risk of infection is the recovery of neutrophil counts,77 In view of the influence of G-CSF and GM-CSF on neutropenia its impact on febrile neutropenia has been evaluated in six ran domized trials in SCLC], four with G-CSF and two w ith GM-CSF (see Table 2 ).7S_W
In the first, 199 patients were treated by six 7H courses of three-weekly CDE. Treatment w ith G-CSF or placebo was given on days 4-17, at a dose of 230 /¿g/m 2. Both severity and duration of neutro penia were significantly reduced and, eoncommitantly, a nearly 50% reduction in incidence of febrile neutropenia, in i.v. antibiotic use, hospitalization and culture confirmed infections was observed. The duration of individual episodes of antibiotic use and hospital stay w ere similar in both treatment groups.
results.
G-CSF in the weekly CODE regimen show ed also a protective effect on number of febrile patients and episodes. 80 The incidence of infection was not reduced during another weekly chem o therapy regimen supported by G-CSF, despite higher white blood cell counts.81 GM-CSF was studied at different dose levels in 238 SCLC patients.82 Hematopoeises was stimulated at all dose levels, but only patients who received 10 /¿g/kg GM-CSF required less i.v. antibiotics com pared with the observation group. Overall fever occurred more frequently in both the 10 and normalization of neutrophil count w ithin 2 weeks 20 /fg/kg GM-CSF groups, and this was considered oe. 63 While on G-CSF, the duration of chemotherapyinduced neutropenia was reduced considerably with after day 1 of chem otherapy. This resulted in a significant reduction in infectious episodes. GM-CSF was evaluated by a similar study design.72
to be a major side-effect of GM-CSF at these dose levels. This and other toxicities were the reason lbr more patients in the GM-CSF group than in the partial abrogation of chem otherapy induced neutro-observation group to drop out of the study. In the penia, GM-CSF failed to reduce the frequency of second GM-CSF trial, the incidence of grade IV febrile episodes. In general 5 -10 /¿g/kg/day G-CSF neutropenia was not significantly different, despite or GM-CSF is advised w h e n prescribed for standard-higher neutrophil nadirs in the GM-CSF arm.H* More dose chemotherapy. The efficacy of G(M>CSF de pends not only on dose but also on schedule of administration, At standard chem otherapy, a 7 -1 0 day administration starting 1 day after the end of chem otherapy is optim al in reducing both degree and duration of leukopenia. A later onset is less effective, an earlier one aggravates leueo-and throm bocytopenia.73 ~7 5 important, patients on GM-CSF spent significantly more days in the hospital, and had a higher incidence of fever, i.v. antibiotic usage, life-threaten ing thrombocytopenia, transfusions, toxic deaths and non-hematologic toxicities.
In conclusion, there is a remarkable difference in the results obtained with G-CSF compared to GM-CSF: in three out of four G-CSF studies the incidence AnlK'uiiccr Drugs • Voi 8 « 7,997 Total dose = percent of planned total dose. aFor references 78-80: percent of patients with at least one episode of fever; for references 82 and 83: percents of patients requiring i.v. antibiotics through all cycles. bNot RDI, but percent of patients whose treatment was completed within 10 weeks (p < 0.05).
* p < 0,001, :i:* p < 0.002, * * * p < 0.01, * * * * p = 0.04 of febrile neutropenia was reduced by almost 50% second study may be due to different patient characwhen compared to no support, while conflicting teristics (younger, m ore often limited disease with a results were reported w ith GM-CSF, The absence of better perform ance status). The incidence of fever in any benefit in the trial of the Southwest Oncology the observation arm in the GM-CSF study was only Group ' may be explained by the concurrent use of 29%, probably due to the lower CDE dosage (doxor-GM-CSF with chest radiotherapy although, on the ubicine 20% and etoposide 33% lower w hen com pared w ith the other two CDE studies),82 An alternative for prophylactic administration of growth factors may be delayed administration of factors, i.e. not until fever has already occurred. The advantage is that overtreatm ent of patients that will never have fever will be prevented. In the few studies that have investigated this concept, both G-CSF and GM-CSF produced a slightly accelerated neutrophil recovery, but this did not result in a reduction in duration of fever and other hand, ameloriation of radiotherapy-induced neutropenia by growth factors has also been re ported.8* 1 Another explanation may be that the occurrence of lever was not infection related but a side-effect of GM-CSF, because the incidence of fever seemed to be GM-CSF dose dependent.82
The incidence of febrile neutropenia is important as it is the critical factor influencing cost effective ness: the probability of hospitalization would have to exceed 40% before the prophylactic use of a growth factor will be cost effective. 5 Febrile neutro penia after conventional CDE doses is reported to occur in 6 .56% of all cycles.**6 The high rate of episodes of febrile neutropenia in the first study may reflect the unusual vigilant monitoring, a stricter definition of febrile neutropenia (i.e. temperature of 38.2°C or greater and absolute neutrophil count below 1.0 X 109/1) and the higher than usual chem o therapy dosage (cyclophosphamide 1000 m g/m 2, doxorubicin 50 m g/m 2 and etoposide 3 X 120 m g/m 2). The somewhat lower incidence in the hospitalization.
87™ 90
A second alternative may be the prophylactic use of antibiotics. In SCLC patients prophylactic co-trimoxazole resulted in a reduced overall incidence of docum ented infections of 60% w hen com pared w ith placebo, especially in case neutrophil count was less than 100 X 106/L Vr,yl It may be w orthw hile to compare directly the protec tive value of growth factors with that of antibiotics, especially from an econom ic point of view.
The prophylactic use of growth factors may facil itate the delivery of planned chemotherapy dose due 554 Antf-Caiiccr Drugs • Voi 8 * 1.997
Intensified treatm ent o f sm all cell lung cancer to less dose reductions and delays, and this was indeed demonstrated in two out of four G-CSF studies, but only to a m oderate degree (see Table  2 ).79,80 Crawford e t a l . reported no data concerning 7 8 delivered dose or dose intensities.
For GM-CSF conflicting observations have been made. Hamm reported that more patients on GM-CSF w ere able to receive full-dose cycles (more than 55% of patients treated during cycles 2 and 3 w ith either 5 or factors (see Table 3 ). In the study of Katakami e t the MTD was not determined without G-CSF and therefore studies with the same chemotherapy regimen have been reported in Table 2 :)Z'9* Although direct comparison is difficult, a moderate dose escalation of carboplatin seems possible with the addition of G-CSF. Luikart tried to escalate etoposide dose besides a constant carboplatin dose, but this was hardly possible with GM-CSF 10 or
The Cancer and Acute Leukemia 10 ¿¿g/kg GM-CSF compared w ith 36% of the observa-20 /<g/.kg/day» tion patients). On the other hand, more patients in Group B reported two separate phase I studies, one the observation arm w ere able to com plete all six cycles (66 versus 60, 42 and 33% of patients w ith 5, H2 <)7 OH w ithout and one w ith the addition of G-CSF.' ' Despite the use of G-CSF, the MTD was the same 10 and 20 //g/kg GM-CSF, respectively). ~ In the trial due to the occurrence of febrile neutropenia as the of concurrent use of GM-CSF and chemoradiotherapy, delivered total dose was even 10% lower in the GM-CSF arm as compared to the control arm. '
In none of these studies w ere significant differ ences in response or survival found, but as these were not primary end-points, sam ple sizes may have been too small to detect small differences and this outcome may also be explained by the inclusion of ED patients.
Growth factors as adjunct to high-dose chemotherapy
It has been attempted to increase the maximum major toxicity. On the other hand, with G-CSF the duration of neutropenia was in general brief and recycling at a three-weekly interval was, therefore, mainly possible in G-CSF-treated patients. The study reported by Paccagnella e t a l . " had an interesting design. The MTD of epirubicin was determined during the first cycle. In the first group of patients the MTD was determ ined without GM-CSF and in the next group of patients it was attempted to increase the MTD by the addition of GM-CSF. The MTD could only be moderately increased with the addition of GM-CSF, i.e. from 60 to 70 m g/m 2, All patients w ere subsequently evaluated for feasibility during the next five cycles. Although this was not a randomized study, comparisons were made between tolerated dose (MTD) by the support of grow th patients treated at a lower epirubicin dose (45 Growth factors as adjunct to accelerated chemotherapy (dose-densified) 60 m g/m 2, without GM-CSF) and at a higher epirubicin dose (60-70 m g/m 2, with GM-CSF). It was demonstrated that the higher close with GM-CSF was not only feasible, but that GM-CSF also had reduced significantly the severity of neutropenia w hen com pared to patients treated at a lower epirubicin dOvSe without GM-CSF (grade IV neutropenia 26 versus 57%, /;<().()!). In patients on GM-CSF, neutropenia in the first course (in which MTD was determined) was more severe than in the next five courses, Due to less dose reductions and delays for hematological 1000 m g /m 2, doxorubicin 50 m g /m 2, vincristine toxicity, the actually delivered DI of epirubicin over 2 mg on day 1; cisplatin 60 m g /m 2 and etoposide six cycles was in the GM-CSF-treated patients sub-150 m g /m 2 on days 8 and 9).100 In the first five stantially increased by 63% when compared to patients GM-CSF w as given as soon as grade IV patients treated without GM-CSF, This resulted also leukopenia developed, while in five additional pa in an increase of relative dose intensity for cisplatin tients the sam e regim en was given w ithout GM-CSF and etoposide of about 30%, despite the same Although n o t one patient was indeed able to receive planned dose for these two agents. Moreover, only the p lanned weekly regimen, the average num ber of 73% of planned cycles could be delivered in the control arm versus 86% of cycles supported by GM-
CSR Patients treated at lower dose levels had an OR
VCG Tjan-Heijnen et ill,
The feasibility of reducing intervals betw een fullplanned-dose chem otherapy courses by the addition of G(M)-CSF has been tested in a few phase II studies (see Table 4 ). Ardizzoni e t a l. reported such an 'accelerated' chem otherapy regimen of CAV and PE, w h ic h w as planned to be alternated weekly lbr a total of six courses (cyclophosphamide 2 days required to recycle was substantially reduced w h en com pared to the standard interval of 21 days (10 days w ith and 13 days without GM-CSF). As a rate of 72% (CR 24%), compared to an OR rate of co n seq u en ce treatm ent duration was limited to 57 95% (CR 40%) in patients treated at higher dose levels.
days w ith GM-CSF and 73 days w ithout GM-CSF (standard projected 107 days), resulting in an almost In conclusion, in these few studies in SCLC it was 2-and 1.5-fold increase in dose intensity, respecshown that the MTD could not or only modestly be tively. A lthough the decrease in treatm ent duration in patients treated w ith GM-CSF was larger than w ithout GM-CSF, it w as disappointing that the over all courses could be increased by 30-60% in absolute benefit of GM-CSF was not as large as one phase II study. More studies are warranted in expected. T he authors suggested, that the 'prophyorder to assess the exact role of growth factors in lactic' use of grow th factors may be m ore suitable chemotherapy dose, instead of 'on-dem and' use. Over all cycles, the increased by the addition of G(M)-CSF. Nevertheless, due to less dose reductions and delays, the total RDI mean white blood cell count and platelet nadirs were 0.60 and 4 6 X 1 0 9/1 in the GM-CSF group versus 0.84 and 105 X I0l)/l in the controls, prob ably reflecting the higher DI in the GM-CSF-treated patients. The increase in DI was not associated w ith chem otherapy at shortened intervals. However, the exact role of growth factor addition should preferably be determined in a randomized fashion and for this reason 65 patients were rando mized to receive VICE (ilbsfamide 5 g /m 2, carbopla-Intensified treatm ent o f sm all cell lung cancer a worsening of non-hematological side-effects. In a tin 300 m g/m , etoposide 120 m g /m 2 on day 1 and subsequent trial, the same group tried to accelerate standard CDE (cyclophosphamide 1000 m g /m 2, dox-2, a w ith or w ithout G-CSF,106 There was not a lixed treatm ent interval planned to maximize DI in both treatment arms in order to determine the exact contribution of G-CSF Retreatment was possible as soon as WBC count was 3*0 X 109/1 or greater and platelet count was 100 X 109/1 or greater. No dose reductions were allowed. It was demonstrated that in both arms dose intensity could be increased compared to the conventional four-weekly schedule: over the first three cycles RDI was 1.34 for the G-300 //g/day day 4 -1 4 in 32 p atien ts111* and lenogras-CSF arm and 1.17 for the control arm (p = 0.001).
Over all six cycles the average RDI was 1.25 and 1.18 per cycle, respectively (p = 0.03). When both arms w ere compared among each other, it was orubicin 45 m g /m , etoposide 3 X 100 m g /irr) by giving it every 2 weeks w ith prophylactic GM-CSF 10//g/kg/day from day 4 to 13.10 The Medical Research Council (MRC) Lung Cancer Working Party performed two comparable studies with CDE, but the chemotherapy was adm inistered at a m oderate higher dose for two agents (doxorubicin 50 m g /m 2 and etoposide 3 X 120 m g /n r2) ,102,103 Moreover, they prescribed G-CSF instead of GM-CSF (filgrastim 102 tim 5 /ig/kg/day day 4 -14 in 20 patients103). The mean chemotherapy interval was 17 days for all three studies. Ardizzoni calculated that the delivered RDI was 1.44 per cycle. It must be rem em bered that shown that only the first two intervals were shor-RDI and intervals can only be calculated over cycles that are actually delivered. Approximately 80% of patients were able to receive at least four cycles, but only 55% were able to c o m p l e t e all six cycles.
Premature discontinuation in all three studies was mainly due to progressive throm bocytopenia and anemia, particularly severe after the fourth cycle. This was also the main reason for delays, w hich were concentrated towards the end of the treatment period. In the MRC studies grade IV neutropenia occurred more often than in the study of Ardizzoni, probably due to the higher doses per course. Never theless, neutropenia had almost invariably resolved by the end of the 14 day period in all three studies tened by 2 -3 days in the G-CSF arm. Thus, the contribution of G-CSF to dose intensity was rather disappointing, despite its statistical significance (1.25/1.18 X 100% = 4-6%), Fifty-five percent of pa tients completed six cycles in both arms. Neutrophil counts w ere consistently higher in G-CSF patients, but in both arms 70% of patients had at least one period of febrile neutropenia. There were more toxic deaths in the G-CSF arm (6 versus 1), Response rates w ere similar, but 2-year survival was better in the G-CSF arm (32 versus 15%), although 32% is not better than usually reported in good prognosis patients.
In conclusion, standard chemotherapy can be and there was no evidence of increasing risk of accelerated both with and without growth factor neutropenia following subsequent cycles. Non-hematologie toxicity was in general mild and manageable. support, simply by giving chemotherapy as soon as blood counts are recovered. The magnitude of Toxic deaths occurred in approximately 10% of acceleration depends on the degree of myeiosuppatients in all three studies. Response rates in the pression produced by a specific regimen. G-CSF MRC] studies seemed similar to conventional regi-seems to improve DI by no more than 10 30% mens. In conclusion, accelerating CDE is feasible but only for a limited (four) num ber of cycles, thereby compromising delivery o f total cumulative dose as projected in standard three-weekly regimens of six courses. A fifth acceleration study has been reported I Q A only in abstract form.
The authors concluded that w hen compared to a maximalized standard-dose regimen. It should be noted that increased DI seems only feasible for the first lour courses due to cumulative thrombocytopenia and anemia. As a consequence total dose in a intensified regimen may even be lower than in a conventional regimen. At the combination of epirubicin 80 m g /m 2 and ifosfa-present it is unclear w hether total dose or DI is the mide 5 g /m 2 could be given at two-weekly instead of three-weekly intervals due to the addition of G-CSF. No details concerning actual mean interval were given.
most important param eter for final outcome. For this reason several collaborative groups have initiated a num ber of randomized trials. The EORTC has started a study, in w hich three-weekly CDE is compared These phase II studies su p p o rt the feasibility of with two-weekly CDE which is supported with G-CSF, In this study standard CDE is given for live chem otherapy cycles were prescribed (etoposide, courses, while the accelerated CDE is given for only four courses at an approximately 25% higher dose per course. By this design the total dose will be equal in both arms, while in the accelerated arm the treatment will be delivered in half the time in comparison with the standard arm. The influence of the 100% dose increase on survival and response will be evaluated, VCG Tjan-Heijnen et al.
Growth factors and peripheral blood progenitor cells
ifosfamide, cisplatin and epirubicin) followed by one 2 h leukapheresis procedure after the second course.115 Subsequently one high-dose course (300% of the conventional schedule, with the replacem ent of cisplatin by carboplatin) was admin istered and this showed to be feasible with PBPC infusion. However, if cure is the goal to be achieved, more than one high-dose cycle is prob ably needed. Shea e t al. demonstrated that multiple courses of high-dose chemotherapy were feasible by the repeated administration of PBPC,1,6 In SCLC one study has reported the sequential administration of PBPC.
, 117
Twenty-five SCLC patients were We have discussed the influence of G(M>CSF on treated w ith six cycles of ICE with G-CSF 300 fig peripheral neutrophil counts. An additional effect is on days 4 -1 5 . PBPC were collected during each a pronounced dose-related increase in peripheral cycle on day 15, by leukapheresis in cohort 1 blood progenitor cells (PBPC), not only including (cryopreservation) and 2 (stored at 4°C), and by venasection in cohort 3 (500-750 ml whole blood stored at 4°C), and reinfused on day 3 of the next cycle. Patients in cohort 1 were treated every 3 gran ulocyte macrophage colony but also erythroid and megakaryocyte KKU07 ^jie meciiailisms by which cytokincs CFCs. increase PBPC are not well understood. Proliferation weeks, and in cohorts 2 and 3 every 2 weeks. ICE resulting in expansion of the population of progeni-chem otherapy with G-CSF was effective in mobiliztor cells, differentiation of stem cells into circulating ing blood progenitors, with a median of 120-fold progenitor ceils and an alteration in adhesion mole-above baseline. The planned DI was 134% for cules on the cell membrane that regulate the release of cells from the marrow into the peripheral blood 108 may all play a role;
Initially, PBPC were only used cohort 1 and 200% for cohort 2 and 3. This could indeed be delivered in the first three cycles, blit only half of patients in cohorts 2 and 3 completed together with AMBT. It was demonstrated before all six courses, compared to two-thirds in cohort 1. that the application of growth factors after ABMT resulted in an accelerated neutrophil recovery, when 109 Toxicity was not significantly different between the three cohorts, The authors concluded that PBPC compared to ABMT alone.,wv The addition of PBPC collected in whole blood without cryopreservation could not further accelerate neutrophil recovery, but is a practical and attractive procedure in chemoplatelet recovery was remarkably faster than in therapy regimens of short duration, using drugs of controls.110 The use of PBPC may therefore facilitate short half-life that are effective in mobilizing blood much larger dose-intensificatlons than achieved by progenitors and have low toxicity for blood stem G(M>CSF or by ABMT Another theoretical advantage cells. The group has opened a phase III study with of PBPC over ABMT may be the lower risk for tumor the cohort 3 schedule as the investigational arm. cell contamination, although concomitant tumor cell recruitment upon mobilization of PBPC has been demonstrated in ED SCLC patients.111 The biologic DlSCllSSion relevance of this observation is not completely understood. To mobilize PBPC, G(M)-C8F can be used either alone or in combination with high-dose
It is apparent that we need better chemotherapy for SCLC, considering the fact that the majority of cyclophosphamide or disease-specific chemotherapy patients will ultimately die of their disease. One By the combination of a growth factor and chemo-approach to improve outcome may be the delivery therapy an even higher num ber of PBPCs can be of chemotherapy at increased dose intensity, either collected, thereby reducing the num ber of necessary leukaphereses.112,113 Not all regimens are equally effective in mobilizing PBPC. It was demonstrated that PE produced a 10-lbkl increase of PBPC, 3 -5 weeks after treatment, while no rebound phase outcome and both factors should therefore be evaluated separately in future trials. Despite promising phase II data concerning mega dose chemotherapy, a survival benefit was seen in only one out of four random ized early-escalation studies (in LD patients). 36 39 In the one randomized late-escalation trial in SCLC, the relapse-free survival after randomization w as significantly better after one high-dose cycle, but there was no m ore than a trend toward improved m edian overall survival. 52 In tw o higher dose equivalent in activity to cyclophospha mide. In soft tissue sarcoma high-dose ifosfamide was demonstrated to circumvent the resistance to standard-dose ifosfamide, while at this dose treat m ent was still manageable using routine clinical This observation re mains difficult to interpret and needs to be conis often not recognized and both approaches are firmed before any conclusion can be made. Carboplatin is the most important cisplatin analog, Significant dose escalation may overcome intrinsic and is less nephro-, neuro* and ototoxic when given * frequently mixed up in the literature.
drug resistance, w hich can be proven by a response after high-dose chem otherapy, not seen after the same chemotherapy at standard dose, The efficacy of high-dose chem otherapy was initially dem on strated in patients w ith acute myeloid leukemia, Iiigh-dose chem otherapy was not yet able to in crease survival in SCLC, but the doses in the phase III trials were substantially lower than the megadoses in the earlier (promising) phase II trials. I j i more recent years high-dose chem otherapy has increasingly used w ith the support of PBPC, and growth factors, in different solid tumors like breast cancer and germ cell tumors. By now, it is not known how many high-dose cycles are needed, but 560 m g /n r).
at a conventional dose. The major side-effect is myelosuppression, especially thrombocytopenia. It is one of the most frequently used agents in high-dose schedules, often in combination with high-dose cyclophosphamide and thiotepa, of which the phase II results are encouraging. However, in patients with advanced (relapsed and previously untreated) ovar ian carcinoma, it was demonstrated that, although the likelihood of tumor response increased with higher carboplatin dose, this relationship was non linear and did not increase significantly above a carboplatin area under the curve (AUC) of 7 mg/nil X min (more or less comparable with Methotrexate and 5-fiuorouracil K 12-i,I2*i it is in general believed that it should be more than are both antimetabolites with increased activity at a one cycle. The use of very high-dose chemotherapy higher dose, but these two agents do not play a is only logical for those agents that have a S-shape major role in the treatment of SCLC. Significant dose dose-response curve of w hich the plateau level has escalation of vincristine is restricted by cumulative not yet been reached. Cyclophospham ide has been neurotoxicity. Adequate high-dose studies with new demonstrated to produce a 3-fold increase in re-antineoplastic agents, like the taxanes and toposponse rate at a 7-fold increase in dose above standard. Ifosfamide is at an approximately 4 times isomerase I inhibitors, have to be awaited. By the second approach, i.e. giving chemotherapy A ) 11A On ì cer Drugs • Vol H > ¡997 at shortened intervals, efficacy may be increased by preventing tumor regrowth during the intervals and also by preventing the development of intrinsic drug resistance during the interval. This approach may be especially worthwhile for tumors like SCLC, that are characterized by rapid growth and marked chemosensitivity. This application may also be useful for drugs that are already at their maximum response level. It is obvious that substantial dose intensification is only possible for those anti-cancer drugs that have myelosuppression as main side-effect. In the older intensification studies autologous bone marrow transplantation was used as rescue, but this proce dure was still accompanied with a significant degree of morbidity and mortality Because G-CSF and GM-CSF are able to reduce duration and severity of neutropenia, it was suggested that the delivery of intensified chemotherapy supported by these factors might be more feasible. However, the addition of growth factors in current dose-escalated or acceler ated schedules seems to result in a relative dose intensity of 110 more than 150% when compared to optimally delivered conventional regimens. At this point cumulative thrombocytopenia becomes a ma jor problem. With the sequential administration of peripheral blood progenitor cells repeated cycles at 200% RDI can be delivered; at this level both hematologic and non-hematologic toxicity become dose limiting. Whether such a degree of dose intensification will improve survival rates has to be awaited from phase III trials. However, w hen reduc tion of neutropenia and/or febrile neutropenia will remain the most important effects of these hemato poietic growth factors, prophylactic administration of antibiotics as adjunct to standard-dose chemo therapy or application of chemotherapy dose reduc tions or delays may be more appropriate, VCG Tjan-Heijnen et al.
